Reports
Sale
Global Parasitic Diseases Therapeutics Market Size, Forecast: By Type: Protozoa, Helminths, Ectoparasite; By Population Type: Children, Adults; By Drug Class: Anthelmintics, Antiprotozoals, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others; Regional Analysis; Patent Analysis; Supplier Landscape; 2024-2032
Global Parasitic Diseases Therapeutics Market Outlook
The global parasitic diseases therapeutics market size was valued at USD 1.79 billion in 2023. Rising disposable incomes, increasing population, and the rising prevalence of parasites are the driving factors of this market. The market is anticipated to grow at a CAGR of 5% during the forecast period 2024-2032 to reach a value of USD 2.77 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Segmentation
Amebiasis, African sleeping disease, trichomoniasis, giardiasis, trypanosomiasis, leishmaniasis, and malaria are all parasitic diseases that need treatment. Based on the product, the parasitic diseases therapeutics market can be divided into:
- Antiprotozoal Therapeutics
- Anthelminthic Therapeutics
- Scabicides And Pediculicides Therapeutics
The EMR report looks into the regional parasitic diseases therapeutics markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
Protozoal, along with helminthic worm diseases, have raised the mortality and morbidity of prophylactic therapy. Preventive chemotherapy is used to monitor the spread within a population of helminthic infections. The high prevalence of malaria worldwide prompted researchers to develop different vaccines to prevent the disease from spreading. Researchers are also developing a variety of prophylactic vaccines to treat and prevent skin leishmaniasis and visceral leishmaniasis. The growing acceptance of these prophylactic vaccines for the prevention and control of parasite diseases is one of the key market developments on parasitic diseases, which would have a positive effect on the market growth.
The occurrence of protozoan, helminth, as well as ectoparasite infections, is rapidly rising. The number of individuals infected with whipworms and hookworms is increasing annually. The number of cases of African trypanosomiasis recorded has also increased considerably, particularly in countries in sub-Saharan Africa like Zambia, Tanzania, Uganda, and Malawi. Likewise, in parts of Central America, South America, and Mexico, the prevalence of Chagas disease is high. In addition, the prevalence of schistosomiasis is also rising globally. The increasing prevalence of these parasites will lead to a growing demand for the treatment of parasites. The antiprotozoal therapeutics segment accounted for the largest market share in 2020.
However, the challenges related to the discovery of antiparasitic drugs and disease diagnosis, increased drug resistance, lack of effective therapies, and side-effects may impede the development of the parasite diseases therapeutics industry in the coming years.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
The report presents a detailed analysis of the following key players in the global parasitic diseases therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- F. Hoffmann-La Roche
- Novartis AG
- GlaxoSmithKline PLC
- Sanofi SA
- Pfizer Inc.
- Others
The EMR report gives an in-depth insight into the parasitic diseases therapeutics market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Population Type |
|
| Breakup by Drug Class |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Parasitic Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Parasitic Diseases Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Parasitic Diseases Epidemiology (2016-2031)
5.3 Europe Parasitic Diseases Epidemiology (2016-2031)
5.4 Asia-Pacific Parasitic Diseases Epidemiology (2016-2031)
5.5 Latin America Parasitic Diseases Epidemiology (2016-2031)
5.6 Middle East & Africa Parasitic Diseases Epidemiology (2016-2031)
6 Parasitic Diseases Therapeutics Market Overview
6.1 Parasitic Diseases Therapeutics Market Historical Value (2017-2023)
6.2 Parasitic Diseases Therapeutics Market Forecast Value (2024-2032)
7 Parasitic Diseases Therapeutics Market Landscape
7.1 Parasitic Diseases Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Parasitic Diseases Therapeutics: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Technology
8 Parasitic Diseases Therapeutics Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Parasitic Diseases Therapeutics Market Segmentation
9.1 Parasitic Diseases Therapeutics Market by Type
9.1.1 Market Overview
9.1.2 Protozoa
9.1.3 Helminths
9.1.4 Ectoparasite
9.2 Parasitic Diseases Therapeutics Market by Population Type
9.2.1 Market Overview
9.2.2 Children
9.2.3 Adults
9.3 Parasitic Diseases Therapeutics Market by Drug Class
9.3.1 Market Overview
9.3.2 Anthelmintics
9.3.3 Antiprotozoals
9.3.4 Others
9.4 Parasitic Diseases Therapeutics Market by Distribution Channel
9.4.1 Market Overview
9.4.2 Hospital Pharmacies
9.4.3 Retail Pharmacies
9.4.4 Online Pharmacies
9.4.5 Others
9.5 Parasitic Diseases Therapeutics Market by Region
9.5.1 Market Overview
9.5.2 North America
9.5.3 Europe
9.5.4 Asia Pacific
9.5.5 Latin America
9.5.6 Middle East and Africa
10 North America Parasitic Diseases Therapeutics Market
10.1 Market Share by Country
10.2 United States of America
10.3 Canada
11 Europe Parasitic Diseases Therapeutics Market
11.1 Market Share by Country
11.2 United Kingdom
11.3 Germany
11.4 France
11.5 Italy
11.6 Others
12 Asia Pacific Parasitic Diseases Therapeutics Market
12.1 Market Share by Country
12.2 China
12.3 Japan
12.4 India
12.5 ASEAN
12.6 Australia
12.7 Others
13 Latin America Parasitic Diseases Therapeutics Market
13.1 Market Share by Country
13.2 Brazil
13.3 Argentina
13.4 Mexico
13.5 Others
14 Middle East and Africa Parasitic Diseases Therapeutics Market
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.4 Nigeria
14.5 South Africa
14.6 Others
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 F. Hoffmann-La Roche
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Novartis AG
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 GlaxoSmithKline PLC
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Sanofi SA
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Pfizer Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
22 Parasitic Diseases Therapeutics - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global parasitic diseases therapeutics market reached a value of USD 1.79 billion in 2023.
The market is anticipated to grow at a CAGR of 5% during the forecast period of 2024-2032 to reach a value of USD 2.77 billion by 2032.
The major drivers of the industry include rising disposable incomes, increasing population, and the rising prevalence of parasites.
The rising initiatives and programmes to eliminate parasitic diseases is expected to be a key trend guiding the growth of the industry.
North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.
The major products of parasitic diseases therapeutics in the industry are antiprotozoal therapeutics, anthelminthic therapeutics, and scabicides and pediculicides therapeutics.
The leading players in the market are F. Hoffmann-La Roche, Novartis AG, GlaxoSmithKline PLC, Sanofi SA, and Pfizer Inc., among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER